Last updated on June 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Brief description of study

Primary Objective: To demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in patients with type 2 diabetes (T2D) who have inadequate glycemic control with metformin. Secondary Objectives: - To compare sotagliflozin versus placebo for: - Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal. - Change from baseline in fasting plasma glucose (FPG); - Change from Baseline in systolic blood pressure (SBP) for patients with baseline SBP ≥130 mmHg; - Change from baseline in SBP for all patients; - Change from baseline in body weight; - Proportion of patients with HbA1c <6.5% and <7.0%. - To evaluate the safety of sotagliflozin versus placebo.

Detailed Study Description

The duration of the study period is up to 87 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks and a 2 week single blind Run-in phase, a 26 week double-blind Core Treatment Period, a 53-week double-blind Extension Period, a 4 week post treatment Follow-up period to collect safety information.

Clinical Study Identifier: NCT02926950

Contact Investigators or Research Sites near you

Start Over

For site information, send an ...

Investigational Site Number 8402032
Salt Lake City, UT United States
  Connect »